A recently published study combining two parallel phase 2 clinical trials assessed olaparib monotherapy in 24 patients with previously treated pancreatic cancer and non-BRCA HR gene alterations (somatic BRCA, germline or somatic ATM, PALB2, ARID1A, PTEN, RAD51, CCNE and FANCB). This evidence concerns the gene PALB2 and familial pancreatic carcinoma.